RayCare in clinical use with CyberKnife at Lausanne University Hospital (CHUV) in Switzerland

RaySearch Laboratories AB (publ) announces that Lausanne Univeristy Hospital (CHUV), Switzerland, has treated their first patient using RayStation®* treatment planning system togheter with the oncology information system RayCare®* in combination with the Accuray CyberKnife® treatment delivery system.

The first treatment – for a patient with brain metastasis – was successfully carried out on June 9.

Lausanne University Hosptial (CHUV) has been a RaySearch customer since 2017. In 2021, the relationship with the clinic was extended as CHUV ordered additional RayStation functionality for automated treatment planning and segmentation using artificial intelligence machine learning techniques, as well as support for CyberKnife planning. At the same time the hospital also decided to invest in RayCare and RaySearch’s oncology analytics system RayIntelligence. RayCare is the key component in order for CHUV to coordinate and optimize its workflows and treatment management and will fully replace the hospital’s previous oncology information system.

CHUV and RaySearch are working together in a program that includes various dimensions of treatment optimization, operational efficiency including optimal machine utilization and the new treatment technique FLASH radiotherapy*. Taking RayCare in clinical use with CyberKnife is an important step forward in this program. CHUV will now, in a phased approach, start using RayCare with their other treatment delivery systems. At its completion, CHUV will conduct all major radiation oncology activities, including treatment planning, record and verify, workflow management and data analytics, exclusively with RaySearch software.

Prof Jean Bourhis, Chair of Radiation Oncology Department at Lausanne University Hospital, says: "This is a first successful step towards transitioning our department to a fully automated platform. Our collaboration with RaySearch will bring more safety and security for our treatments."

Johan Löf, founder and CEO, RaySearch, says: “I am very pleased to hear that the first treatment with CyberKnife using RayStation and RayCare has been successfully carried out at this world-class center. I am impressed by the ambitious program at CHUV and we are happy to support them with a complete software suite that enables optimization of operational efficiency and improved treatment quality.”

Suzanne Winter, President and CEO, Accuray, says: “On behalf of the global Accuray team I congratulate Prof. Bourhis and his colleagues on the treatment of their first patient using the CyberKnife System, RayStation and RayCare. The integration of RayCare with our advanced radiation delivery system will provide additional flexibility and expanded options for treating the high volume of patients the CHUV team sees daily in their practice. We value our long-term partnership with CHUV and look forward to continuing to work with them to optimize patient care.”

For more information, please contact:
Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00
johan.lof@raysearchlabs.com

About Lausanne University Hospital (CHUV)
Lausanne University Hosptial (CHUV) in Lausanne is, together with Geneva, Bern, Basel and Zürich, one of the five university hospitals in Switzerland. With its 16 clinical and medio-technical departments and their numerous services, the CHUV is renowned for its academic achievements in healthcare, research and teaching.

The CHUV is also a well-known center of medical education and research thanks to its collaboration with the Faculty of Biology and Medicine of the University of Lausanne and the Swiss Federal Institute of Technology in Lausanne (EPFL). Together, these institutions form a vast campus in the Lake Geneva region.

About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.  

RaySearch's software has been sold to over 900 clinics in more than 40 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at raysearchlabs.com.

About RayStation
RayStation®* is a flexible, innovative treatment planning system, chosen by many leading cancer centers worldwide. It combines unique features such as unmatched adaptive therapy capabilities, multi-criteria optimization, market-leading algorithms for treatment plan optimization for HDR brachytherapy and external beam therapy with photons, electrons, and protons, as well as helium and carbon ions. RayStation supports a wide range of treatment machines, providing one control center for all treatment planning needs and ensuring centers get greater value from existing equipment. RayStation also seamlessly integrates with RayCare®*. By harmonizing the treatment planning, the care of cancer patients worldwide is improved.

About RayCare
The RayCare®* oncology information system (OIS) is designed to support the many complex logistical challenges faced by today’s oncology clinics. RayCare is closely integrated with RayStation®* and provides seamless access to all the powerful planning tools in RayStation and RayCommand®. The system efficiently coordinates activities in radiation therapy and offers advanced features for clinical workflow automation, and adaptive radiation therapy. RayCare responds to the demand from clinics for a more user-friendly and workflow-oriented information system that can support the cancer care of the future. 

* Subject to regulatory clearance in some markets.

Tags: